Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation

ABSTRACT Hypoxic stress, like DNA damage, induces p53 protein accumulation and p53-dependent apoptosis in oncogenically transformed cells. Unlike DNA damage, hypoxia does not induce p53-dependent cell cycle arrest, suggesting that p53 activity is differentially regulated by these two stresses. Here we report that hypoxia induces p53 protein accumulation, but in contrast to DNA damage, hypoxia fails to induce endogenous downstream p53 effector mRNAs and proteins. Hypoxia does not inhibit the induction of p53 target genes by ionizing radiation, indicating that p53-dependent transactivation requires a DNA damage-inducible signal that is lacking under hypoxic treatment alone. At the molecular level, DNA damage induces the interaction of p53 with the transcriptional activator p300 as well as with the transcriptional corepressor mSin3A. In contrast, hypoxia primarily induces an interaction of p53 with mSin3A, but not with p300. Pretreatment of cells with an inhibitor of histone deacetylases that relieves transcriptional repression resulted in a significant reduction of p53-dependent transrepression and hypoxia-induced apoptosis. These results led us to propose a model in which different cellular pools of p53 can modulate transcriptional activity through interactions with transcriptional coactivators or corepressors. Genotoxic stress induces both kinds of interactions, whereas stresses that lack a DNA damage component as exemplified by hypoxia primarily induce interaction with corepressors. However, inhibition of either type of interaction can result in diminished apoptotic activity.

[1]  A. Giaccia,et al.  Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. , 1999, Cancer research.

[2]  L. Bracco,et al.  The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.

[3]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[4]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  K. Sakaguchi,et al.  DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.

[6]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[7]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[8]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[9]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[10]  N. Hay,et al.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.

[11]  C. Harris,et al.  The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. , 1996, Genes & development.

[12]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[13]  D. Meek,et al.  Multisite phosphorylation and the integration of stress signals at p53. , 1998, Cellular signalling.

[14]  M. Yoshida,et al.  Selective Induction of Cyclin‐Dependent Kinase Inhibitors and Their Roles in Cell Cycle Arrest Caused by Trichostatin A, an Inhibitor of Histone Deacetylase , 1999, Annals of the New York Academy of Sciences.

[15]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[16]  P. Olive,et al.  The comet assay: a comprehensive review. , 1995, Mutation research.

[17]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[18]  Y Taya,et al.  DNA damage induces phosphorylation of the amino terminus of p53. , 1997, Genes & development.

[19]  T. Unger,et al.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.

[20]  K. Gardner,et al.  Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.

[21]  T. Graeber,et al.  Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status , 1994, Molecular and cellular biology.

[22]  S. Schreiber,et al.  A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Prives.  Signaling to p53 Breaking the MDM2–p53 Circuit , 1998, Cell.

[24]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[25]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[26]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[27]  E. White,et al.  Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein , 1995, Molecular and cellular biology.

[28]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[29]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[30]  M. Yoshida,et al.  Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. , 1990, Journal of Biological Chemistry.

[31]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[32]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[33]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[34]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[35]  P. Baeuerle,et al.  Hypoxia Induces c-fos Transcription via a Mitogen-activated Protein Kinase-dependent Pathway* , 1997, The Journal of Biological Chemistry.

[36]  K. Vousden,et al.  Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest , 1998, Molecular and Cellular Biology.

[37]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[38]  Y Taya,et al.  DNA damage‐inducible phosphorylation of p53 at N‐terminal sites including a novel site, Ser20, requires tetramerization , 1999, The EMBO journal.

[39]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[40]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[41]  A. Levine,et al.  Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. , 1999, Genes & development.

[42]  A. Levine,et al.  Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction , 1999, Oncogene.

[43]  P. Howley,et al.  Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation , 1997, Molecular and cellular biology.

[44]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[45]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[46]  E. May,et al.  Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. , 1995, Oncogene.

[47]  C. Prives,et al.  Functional interaction between p53, the TATA-binding protein (TBP), andTBP-associated factors in vivo , 1996, Molecular and cellular biology.

[48]  Erwin G. Van Meir.  Hypoxia-mediated selection of cells with diminished apoptotic potential to solid tumours. , 1996, Neurosurgery.

[49]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[50]  K. Vousden,et al.  Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.

[51]  D. Israeli,et al.  Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression , 1998, Nature Medicine.

[52]  P. Howley,et al.  Mutations in serines 15 and 20 of human p53 impair its apoptotic activity , 1999, Oncogene.

[53]  S. Bhattacharya,et al.  Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. , 1999, Genes & development.

[54]  Xinbin Chen,et al.  Identification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis* , 1998, The Journal of Biological Chemistry.

[55]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.